Article
Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study.
The Lancet. Oncology - 1 Jun 2015
Konecny Gottfried E, Finkler Neil, Garcia Agustin A, Lorusso Domenica, Lee Paula S, Rocconi Rodney P, Fong Peter C, Squires Matt, Mishra Kaushal, Upalawanna Allison, Wang Yongyu, Kristeleit Rebecca
Abstract excerpt
BACKGROUND: Activating FGFR2 mutations are found in 10-16% of primary endometrial cancers and provide an opportunity for targeted therapy. We assessed the safety and activity of dovitinib, a potent tyrosine-kinase inhibitor of fibroblast growth factor receptors, VEGF receptors, PDGFR-β, and c-KIT, as second-line therapy both in patients with FGFR2-mutated (FGFR2(mut)) endometrial cancer and in those with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.